Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 12 studies | 30% ± 12% | |
astrocyte | 12 studies | 35% ± 17% | |
oligodendrocyte precursor cell | 11 studies | 36% ± 16% | |
glutamatergic neuron | 10 studies | 52% ± 25% | |
fibroblast | 9 studies | 25% ± 10% | |
GABAergic neuron | 8 studies | 42% ± 25% | |
adipocyte | 8 studies | 25% ± 7% | |
oligodendrocyte | 8 studies | 31% ± 12% | |
interneuron | 7 studies | 38% ± 25% | |
epithelial cell | 7 studies | 35% ± 16% | |
microglial cell | 6 studies | 28% ± 7% | |
macrophage | 5 studies | 24% ± 4% | |
ciliated cell | 5 studies | 26% ± 8% | |
pericyte | 5 studies | 21% ± 7% | |
smooth muscle cell | 5 studies | 24% ± 8% | |
type I pneumocyte | 5 studies | 26% ± 6% | |
type II pneumocyte | 5 studies | 21% ± 5% | |
neuron | 4 studies | 46% ± 19% | |
Mueller cell | 4 studies | 29% ± 7% | |
club cell | 4 studies | 26% ± 10% | |
endothelial cell of lymphatic vessel | 4 studies | 27% ± 3% | |
basal cell | 4 studies | 34% ± 17% | |
GABAergic interneuron | 3 studies | 22% ± 1% | |
neural progenitor cell | 3 studies | 34% ± 5% | |
connective tissue cell | 3 studies | 19% ± 1% | |
ependymal cell | 3 studies | 31% ± 14% | |
goblet cell | 3 studies | 35% ± 21% | |
transit amplifying cell | 3 studies | 37% ± 29% | |
brush cell | 3 studies | 37% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 2266.91 | 459 / 459 | 100% | 22.87 | 1118 / 1118 |
esophagus | 100% | 2491.81 | 1445 / 1445 | 100% | 12.42 | 183 / 183 |
ovary | 100% | 4646.46 | 180 / 180 | 100% | 18.41 | 430 / 430 |
prostate | 100% | 2797.84 | 245 / 245 | 100% | 15.78 | 502 / 502 |
brain | 100% | 4049.90 | 2641 / 2642 | 100% | 21.66 | 705 / 705 |
uterus | 100% | 3261.81 | 170 / 170 | 100% | 16.06 | 458 / 459 |
intestine | 100% | 2656.09 | 966 / 966 | 100% | 11.07 | 525 / 527 |
bladder | 100% | 2571.81 | 21 / 21 | 100% | 12.73 | 502 / 504 |
lung | 99% | 1677.53 | 575 / 578 | 100% | 14.25 | 1154 / 1155 |
skin | 100% | 2585.70 | 1808 / 1809 | 99% | 13.08 | 469 / 472 |
stomach | 100% | 1974.55 | 359 / 359 | 99% | 11.09 | 284 / 286 |
thymus | 100% | 1859.35 | 652 / 653 | 99% | 15.86 | 601 / 605 |
kidney | 100% | 1663.15 | 89 / 89 | 99% | 10.07 | 889 / 901 |
pancreas | 99% | 1371.66 | 325 / 328 | 99% | 11.38 | 177 / 178 |
adrenal gland | 100% | 5887.90 | 258 / 258 | 98% | 13.85 | 225 / 230 |
liver | 79% | 540.75 | 179 / 226 | 79% | 5.76 | 322 / 406 |
adipose | 100% | 1981.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 14.25 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 15.11 | 29 / 29 |
spleen | 100% | 1531.24 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 10.32 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.67 | 1 / 1 |
blood vessel | 100% | 2217.10 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 94% | 859.56 | 757 / 803 | 0% | 0 | 0 / 0 |
heart | 93% | 1057.53 | 799 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 26% | 717.67 | 245 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0010971 | Biological process | positive regulation of G2/M transition of mitotic cell cycle |
GO_2000736 | Biological process | regulation of stem cell differentiation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_1904197 | Biological process | positive regulation of granulosa cell proliferation |
GO_0006338 | Biological process | chromatin remodeling |
GO_0042659 | Biological process | regulation of cell fate specification |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_1990739 | Biological process | granulosa cell proliferation |
GO_0000086 | Biological process | G2/M transition of mitotic cell cycle |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0016581 | Cellular component | NuRD complex |
GO_0005634 | Cellular component | nucleus |
GO_0043565 | Molecular function | sequence-specific DNA binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
GO_0042826 | Molecular function | histone deacetylase binding |
Gene name | MTA3 |
Protein name | Metastasis associated 1 family member 3 Metastasis-associated protein MTA3 Metastasis associated 1 family member 3 (Metastasis associated 1 family, member 3, isoform CRA_a) |
Synonyms | KIAA1266 hCG_1783907 |
Description | FUNCTION: Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin . Plays a role in maintenance of the normal epithelial architecture through the repression of SNAI1 transcription in a histone deacetylase-dependent manner, and thus the regulation of E-cadherin levels . Contributes to transcriptional repression by BCL6 . . |
Accessions | C9JR73 ENST00000405094.2 [Q9BTC8-1] E9PCS8 ENST00000454356.5 F6RRE2 ENST00000409019.5 ENST00000406652.5 ENST00000407270.7 [Q9BTC8-2] ENST00000405592.5 ENST00000430763.5 ENST00000406911.5 ENST00000433553.5 E7EV10 E9PF88 Q9BTC8 E7EQY4 |